common.skip_to_content
USE CODE MUNCHMAKERS FOR 10% OFF YOUR FIRST ORDER (650) 955-1836 Closed · back Thu 8am PT | REQUEST A CALLBACK
USE MUNCHMAKERS FOR 10% OFF YOUR FIRST ORDER

New Bipartisan Bill Targets Delta-8 THC While Preserving CBD Market

Hemp Guardrails Act would ban synthetic cannabinoids, establish federal oversight for hemp-derived products

Congressional lawmakers introduced bipartisan legislation Thursday aimed at banning delta-8 THC, delta-10 THC, and THC-O products while establishing federal regulations for hemp-derived cannabinoids.

The Hemp Guardrails Act represents the latest attempt to address the regulatory chaos created by the 2018 Farm Bill, which legalized hemp but left a gaping loophole for intoxicating cannabinoids. Since then, delta-8 THC products have exploded across gas stations and smoke shops nationwide, operating in a legal gray zone that's frustrated both cannabis operators and regulators.

Under the proposed legislation, qualifying CBD products would remain legal and accessible. The bill seeks to draw a clear line between non-intoxicating hemp products and synthetic or semi-synthetic cannabinoids that produce psychoactive effects similar to traditional marijuana.

The Regulatory Gap

The 2018 Farm Bill legalized hemp containing less than 0.3% delta-9 THC by dry weight. But it said nothing about other cannabinoids that could be derived from legal hemp through chemical conversion processes. Enterprising manufacturers quickly filled that void, creating a multi-billion dollar market for products like delta-8 THC gummies and vapes.

State regulators have responded with a patchwork of conflicting rules. Some states have banned these products outright. Others have attempted to regulate them. Many have done nothing at all, leaving consumers and businesses in limbo.

Licensed cannabis operators have complained for years that delta-8 products undercut their heavily taxed and regulated businesses. These hemp-derived products face minimal oversight, no potency testing requirements, and can be sold to adults in states where marijuana remains illegal.

What the Bill Would Change

The Hemp Guardrails Act would give the Food and Drug Administration authority to regulate hemp-derived cannabinoid products. This includes setting standards for manufacturing, testing, labeling, and sales restrictions.

Delta-8 THC, delta-10 THC, and THC-O would be explicitly prohibited under the legislation. These cannabinoids are typically created through chemical processes that convert CBD into psychoactive compounds. Critics argue these products were never intended to be legal under the Farm Bill's hemp provisions.

CBD products that meet federal standards would continue to be sold legally. The bill aims to preserve the legitimate hemp industry while closing loopholes that allowed intoxicating products to proliferate without safety oversight.

Industry Stakes

The hemp-derived THC market has grown into a significant economic force since 2018. Thousands of businesses now depend on delta-8 and similar products for revenue. A federal ban would force these companies to pivot or shut down entirely.

For state-licensed cannabis operators, the bill could eliminate competition from unregulated intoxicating products. But it also sets a precedent for federal intervention in cannabinoid markets that some industry advocates view warily.

The legislation's bipartisan sponsorship suggests genuine momentum for addressing the hemp THC issue. Previous attempts to regulate these products have stalled amid disagreements over how to balance consumer access, public safety, and economic interests.

What Happens Next

The bill now heads to committee, where it will face scrutiny from lawmakers on both sides of the aisle. Hemp industry groups are expected to lobby against provisions that would eliminate delta-8 products, while cannabis trade associations will likely support stricter regulations.

Timing matters. If the legislation gains traction, it could reshape the hemp market before the end of the current congressional session. But hemp regulatory bills have died in committee before, and there's no guarantee this one will be different.

The FDA would need to develop and implement new regulatory frameworks if the bill passes. That process could take months or years, leaving businesses and consumers in continued uncertainty even after legislation clears Congress.


This article is based on original reporting by mjbizdaily.com.

More from Alex Morgan